AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01380327 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cockroach Sublingual Immunotherapy (SLIT) - Low Dose
Description: Participants are randomized to receive daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume \[w/v\] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to three escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.
Study NCT01380327 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants are randomized to receive either daily (low dose) or twice-daily (high dose) placebo treatment placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The placebo was also administered during the preliminary dosing visits, up to three or seven escalating doses, or until the maximum study dose (420 or 840 microliters, 1:20 weight per volume \[w/v\]) was achieved.
Study NCT01380327 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cockroach Sublingual Immunotherapy (SLIT) - High Dose
Description: Participants are randomized to receive twice-daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume \[w/v\] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to seven escalating doses, or until the maximum study dose (840 microliters, 1:20 w/v) was achieved.
Study NCT00476476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Orally every day for about 4-6 weeks
Study NCT02271126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEG monitoring
Description: anticoagulation monitoring during ECMO will be according to TEG
Study NCT02271126 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: APTT monitoring
Description: anticoagulation monitoring during ECMO will be according to aPTT
Study NCT02271126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Anticoagulation provided to patients in ECMO
Study NCT02271126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Anticoagulation provided to patients in ECMO
Study NCT03056755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: 300 mg of alpelisib film-coated tablets administered orally once daily
Study NCT03056755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg of fulvestrant via intramuscular injection administered on Days 1, 15 on Cycle 1 and Day 1 at each cycle thereafter. Cycle=28 days
Study NCT03056755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg of letrozole film-coated tablets administered orally once daily
Study NCT03056755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: 3.6 mg of goserelin via injectable subcutaneous implant administered every 28 days. Only for men in Cohort B and premenopausal women.
Study NCT03056755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: 7.5 mg of leuprolide via injectable intramuscular depot administered every 28 days. Only for men in cohort B and premenopausal women.
Study NCT03713593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Administered orally once a day
Study NCT03713593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenvatinib
Description: Administered orally once a day
Study NCT03713593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an IV infusion on Day 1 Q3W
Study NCT03713593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline placebo
Description: Administered as an IV infusion on Day 1 Q3W
Study NCT03923959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid Injectable Solution
Description: 100 cc normal saline mixed with 1g of tranexamic acid in solution
Study NCT03923959 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 cc normal saline
Study NCT02964936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: Oral administration
Study NCT04515576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269
Description: Administered SC
Study NCT04515576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC
Study NCT04515576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT04405934 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures
Description: Rapid or standard (time to return to sites) receipt of virus (Covid-19) genomic sequencing reports
Study NCT02706002 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fluoroscopy
Description: in active group femural stem of hip prosthesis will implanted under fluoroscopy guidance during operation till maximum rasp size reached that fills the medullary canal. ordinary 3-5 sequences per operation
Study NCT02706002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hip prosthesis
Description: all patients in the study will undergo hip prosthesis
Study NCT02706002 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: hip prosthesis
Description: all patients in the study will undergo hip prosthesis
Study NCT00902824 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ADVAX
Description: Receive 4mg ADVAX at Months 0, 1, and 2 (Biojector), and receive boost of 5x10\^7 pfu TBC-M4 (IM)
Study NCT00902824 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TBC-M4
Description: Receive 5x10\^7 pfu TBC-M4 (IM) at Months 0, 1, and 6.
Study NCT00902824 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group A (n=4) will receive the ADVAX placebo (formulation buffer) via Biojector.~Group B (n=4) will receive the TBC-M4 placebo (formulation buffer) via IM.
Study NCT02168270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ascorbic acid
Description: Given IV
Study NCT02168270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO
Study NCT02168270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02168270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03276910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPREX
Description: 6 doses at 50 IU/kg or 20 IU/kg in subcutaneous use
Study NCT03276910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride AGUETTANT 0.9%
Description: 6 injections at 1ml in subcutaneous use
Study NCT02561988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Study NCT02565485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's
Description: 1500 cc of IV Fluid (crystalloid) used for preload prior to epidural administration in the treatment arm. Control arm receives 500 cc.
Study NCT03677778 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline injected via interscalene nerve catheter
Description: With the catheter covered, treatment group patients will receive a normal saline (NS) bolus regimen (30cc 0.9% NS) via their interscalene nerve block catheter.
Study NCT03677778 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: With the catheter covered, placebo group patients will go through the same steps as the treatment group, but no solution will be injected into the interscalene nerve block catheter.
Study NCT02103647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate release capsule(lyrica 150mg * 2/day)
Description: Immediate release capsule
Study NCT02103647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sustained release tablet
Description: sustained release tablet
Study NCT01710852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS CRP Rx
Study NCT01710852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00789802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal estradiol
Description: transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.
Study NCT00789802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxen
Description: naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks
Study NCT00789802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo
Description: oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks
Study NCT04158830 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin 81 mg Enteric Coated Tab - 1 tablet
Description: take one (1) 81 mg tablet each evening
Study NCT04158830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg Enteric Coated Tab - 2 tablets
Description: take two (2) 81 mg tablets each evening
Study NCT00377026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: Lifestyle modification including individual sessions with an interventionist to discuss dietary intake and exercise. Group sessions with other participants randomized to the lifestyle intervention to discuss lifestyle modification and group exercise.
Study NCT02318485 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Limbal epithelial stem cell graft
Study NCT03264989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizanlizumab
Description: Crizanlizumab was administered IV infusion over 30 minutes at the assigned dose on Week 1 Day 1, Week 3 Day 1, and then Day 1 of every 4-week cycle. Cycle = 28 days
Study NCT01919008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: Oral
Study NCT04172038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy will be delivered using a guideline-concordant approach based off the Department of Defense -Veterans Affairs Low Back Pain Guidelines, focusing on risk-stratified care deliver (using the STarT Back tool as an adjunct).
Study NCT04172038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move 2 Health (M2H)
Description: Participants will receive education for self-management (video and written materials) to introduce the key domains of holistic health in the Move to Health (M2H) model and their relationship to chronic LBP. Next, the participant will complete a Personal Health Inventory. The Inventory will be reviewed by the health coach and patient in order to identify specific domains for priority based on patient preference:~1. Sleep~2. Physical Activity~3. Nutrition~4. Intrinsic Well-Being (Personal Development, Spiritual Well-Being, Emotional Well-Being)~5. Extrinsic Well-Being (Family/Social Relationships, Surroundings)~Care may range from guided self-management with the researcher to a specialist referral (e.g., sleep specialist, dietician, behavioral health provider, etc.).
Study NCT04172038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MORE Mindfulness
Description: Throughout the intervention, three core areas are emphasized. Activities include exercises and at-home work for participants to reinforce these core areas.~1. Mindfulness~2. Cognitive reappraisal~3. Savoring of positive experiences
Study NCT03785600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morning Bright Light Therapy
Description: Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 90 minutes of waking up.
Study NCT03785600 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Negative Ion Generator
Description: Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 90 minutes of waking up.
Study NCT04026555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MEWS++ Monitoring
Description: Patient's electronic medical record data will undergo processing by a machine learning algorithm (MEWS++).
Study NCT04026555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Predictor Score
Description: A score predicting the likelihood that the patient will experience a deterioration in their clinical condition within six hours will be generated. If the prediction score exceeds a predetermined threshold, an alert will be sent to the provider. The alerting protocol is tiered, with both a low and high threshold. If the score is above the low threshold, nursing will be notified. If the score is above the high threshold, RRT will be notified.
Study NCT04026555 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Predictor Score
Description: A score predicting the likelihood that the patient will experience a deterioration in their clinical condition within six hours will be generated. If the prediction score exceeds a predetermined threshold, an alert will be sent to the provider. The alerting protocol is tiered, with both a low and high threshold. If the score is above the low threshold, nursing will be notified. If the score is above the high threshold, RRT will be notified.
Study NCT04219280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quillivant XR
Description: Long-lasting liquid solution of Quillivant XR.
Study NCT04219280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid solution to mimic the color and taste of Quillivant XR.
Study NCT02716246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UX111
Description: Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.
Study NCT02716246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Immunomodulatory (IM) Therapy
Study NCT02716246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Prophylactic IM Therapy
Study NCT02716246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant IM Therapy
Description: The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy.
Study NCT00782340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
Study NCT00782340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droxidopa
Description: 100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
Study NCT02669823 — intervention group
Intervention type: OTHER
Intervention: None, treatment as actual best practice
Study NCT02904304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine+Phenylephrine+Ibuprofen
Description: 01 tablet, orally, every 12 hours.
Study NCT02904304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 01 tablet, orally, every 12 hours.
Study NCT02775526 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TOT
Description: 70 patients
Study NCT02775526 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT
Description: 70 patients
Study NCT02775526 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Burch Colposuspension
Description: 70 patients
Study NCT00872144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex
Description: Sativex (or placebo) will be dispensed identical 5.5 ml containers. Participants will be instructed to start with a dose of 1 spray trans-mucosally at 1800 hrs. If there are no limiting adverse effects such as sedation or dizziness, participants will be instructed to increase the dose to 2 sprays- one in the morning and the other in the early evening on day two. Participants may increase the dose by 1-2 sprays per day to a maximum dose of 12 sprays per day given 3 sprays 4 times per day. In the initial titration phase participants will be instructed to space each dose actuation 15 minutes apart until accustomed to the preparation. Participants will titrate the dose to a level where they obtain an analgesic effect without limiting side effects.
Study NCT03807310 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Targeted nutrient supplementation (Long-drink)
Description: Once daily for at least 12 months
Study NCT03807310 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Once daily for at least 12 months
Study NCT03807310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling
Description: Counselling on healthy lifestyle (in particular physical activity, smoking cessation) and weight management by motivational interviewing
Study NCT02323659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate 20mg per dose, administered orally, once every week
Study NCT02323659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Alfa-2b
Description: Interferon Alfa-2b 3 million international units (MIU), administered 3 times per week
Study NCT05139966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mouthwash Product
Description: The participants were requested to rinse 10 ml of the mouthwash 2 times / day (morning and evening) for 1 min after toothbrushing (a non-F dentifrice was used throughout the study).
Study NCT05139966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouthwash Product
Description: The participants were requested to rinse 10 ml of the mouthwash 2 times / day (morning and evening) for 1 min after toothbrushing (a non-F dentifrice was used throughout the study).
Study NCT00276874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole; 0-30 mg; oral; daily
Study NCT00276874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo; 0 mg; oral; daily
Study NCT02081170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrate
Description: 1. pars plana vitrectomy~2. internal limiting membrane removal~3. Fluid-air exchange~4. Intravitreal autologous platelet concentrate injection~5. Intravitreal gas (14% C3F8) injection~6. Keep prone position for 7-14 days after surgery
Study NCT04134975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spine surgery
Description: surgery with pedicle screw placement between L1 and S1
Study NCT04134975 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spine surgery
Description: surgery with pedicle screw placement between L1 and S1
Study NCT00669149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bivalirudin + clopidogrel + aspirin
Study NCT04554316 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Steri-strip
Description: Steri-Strips (3M Health Care, St. Paul, Minn) are a commonly used means of covering surgical incisions following many operations. Use of adhesive surgical tape over incisions maintains epidermal approximation in primary skin closure while limiting exposure to the environment, theoretically improving cosmesis and limiting risk of infection.
Study NCT04576793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-ER176
Description: 11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. 11C-ER176 will be administered at activity up to 20 millicurie (mCi) per injection.
Study NCT04576793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-ER176
Description: 11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. 11C-ER176 will be administered at activity up to 20 millicurie (mCi) per injection.
Study NCT04576793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-MK6240
Description: MK-6240 measures a protein called in the brain. MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.